|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Trametinib
gptkb:trametinib
|
|
gptkbp:activities
|
MEK inhibitor
|
|
gptkbp:approves
|
gptkb:2013
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:Tafinlar
|
|
gptkbp:category
|
gptkb:D
not recommended
|
|
gptkbp:class
|
kinase inhibitor
|
|
gptkbp:clinical_trial
|
Phase III
monotherapy or in combination
|
|
gptkbp:contraindication
|
hypersensitivity to trametinib
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
until disease progression
|
|
gptkbp:excretion
|
biliary
|
|
gptkbp:financial_products
|
D B09080
|
|
gptkbp:has_ability
|
0.5 mg
2 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mekinist
|
|
gptkbp:indication
|
BRAF V600 E or V600 K mutation-positive melanoma
|
|
gptkbp:ingredients
|
gptkb:trametinib
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_atype_of
|
L01 X E30
|
|
gptkbp:is_monitored_by
|
cardiac function
liver function tests
|
|
gptkbp:is_used_for
|
treatment of melanoma
|
|
gptkbp:lifespan
|
approximately 4.5 days
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:market
|
gptkb:stock_market_index
|
|
gptkbp:marketed_as
|
gptkb:Mekinist
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:name
|
Essential Medicines List
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:population
|
adults and pediatric patients
|
|
gptkbp:provides_information_on
|
included in NCCN guidelines
|
|
gptkbp:research_focus
|
combination therapies
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
thromboembolic events
edema
interstitial lung disease
serious skin reactions
ocular toxicities
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for efficacy
|